Pulse Methylprednisolone Versus Dexamethasone in COVID-19: A Multicenter Cohort Study.
COVID-19
dexamethasone
methylprednisolone
mortality
pulse therapy
Journal
Critical care explorations
ISSN: 2639-8028
Titre abrégé: Crit Care Explor
Pays: United States
ID NLM: 101746347
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
medline:
1
4
2023
entrez:
31
3
2023
pubmed:
1
4
2023
Statut:
epublish
Résumé
Although pulse (high-dose) methylprednisolone therapy can hypothetically control immune system flare-ups effectively, the clinical benefit of pulse methylprednisolone compared with dexamethasone in COVID-19 remains inconclusive. To compare pulse methylprednisolone to dexamethasone as a COVID-19 treatment. Using a Japanese multicenter database, we identified adult patients admitted for COVID-19 and discharged between January 2020 and December 2021 treated with pulse methylprednisolone (250, 500, or 1,000 mg/d) or IV dexamethasone (≥ 6 mg/d) at admission day 0 or 1. The primary outcome was in-hospital mortality. Secondary outcomes were 30-day mortality, new ICU admission, insulin initiation, fungal infection, and readmission. Multivariable logistic regression was conducted to differentiate the dose of pulse methylprednisolone (250, 500, or 1,000 mg/d). Additionally, subgroup analyses by characteristics such as the need for invasive mechanical ventilation (IMV) were also conducted. A total of 7,519, 197, 399, and 1,046 patients received dexamethasone, 250, 500, and 1,000 mg/d of methylprednisolone, respectively. The crude in-hospital mortality was 9.3% (702/7,519), 8.6% (17/197), 17.0% (68/399), and 16.2% (169/1,046) for the different doses, respectively. The adjusted odds ratio (95% CI) was 1.26 (0.69-2.29), 1.48 (1.07-2.04), and 1.75 (1.40-2.19) in patients starting 250, 500, and 1,000 mg/d of methylprednisolone, respectively, compared with those starting dexamethasone. In subgroup analyses, the adjusted odds ratio of in-hospital mortality was 0.78 (0.25-2.47), 1.12 (0.55-2.27), and 1.04 (0.68-1.57) in 250, 500, and 1,000 mg/d of methylprednisolone, respectively, among patients with IMV, whereas the adjusted odds ratio was 1.54 (0.77-3.08), 1.62 (1.13-2.34), and 2.14 (1.64-2.80) among patients without IMV. Higher doses of pulse methylprednisolone (500 or 1,000 mg/d) may be associated with worse COVID-19 outcomes when compared with dexamethasone, especially in patients not on IMV.
Identifiants
pubmed: 36998527
doi: 10.1097/CCE.0000000000000886
pmc: PMC10047604
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0886Informations de copyright
Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.
Déclaration de conflit d'intérêts
The authors have disclosed that they do not have any potential conflicts of interest.
Références
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Respiration. 2021;100(2):116-126
pubmed: 33486496
Chest. 2021 Mar;159(3):1019-1040
pubmed: 33129791
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Respirology. 2018 Nov;23(11):1041-1048
pubmed: 30011421
J Clin Med. 2021 Dec 26;11(1):
pubmed: 35011857
Ann N Y Acad Sci. 2014 May;1318:1-6
pubmed: 24611742
PLoS One. 2021 May 25;16(5):e0252057
pubmed: 34033648
Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v69-v81
pubmed: 33280011
Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):680-688
pubmed: 35324035
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Am J Epidemiol. 2008 Feb 15;167(4):492-9
pubmed: 18056625
Am J Med. 2020 Oct;133(10):e568-e574
pubmed: 32278843
Antibiotics (Basel). 2021 Oct 06;10(10):
pubmed: 34680795
Ann Rheum Dis. 2009 Jul;68(7):1119-24
pubmed: 18684744
Mycoses. 2021 Sep;64(9):993-1001
pubmed: 33896063
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
BMJ. 2021 Sep 23;374:n2219
pubmed: 34556469
Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30
pubmed: 23947590
BMC Infect Dis. 2021 Apr 10;21(1):337
pubmed: 33838657
JAMA. 2020 Oct 6;324(13):1298-1306
pubmed: 32876689
J Epidemiol Community Health. 2021 Feb;75(2):205-206
pubmed: 33023971
Mycopathologia. 2022 Jun;187(2-3):271-289
pubmed: 35312945
J Clin Med. 2021 Sep 28;10(19):
pubmed: 34640481
Lancet Reg Health West Pac. 2022 Mar;20:100365
pubmed: 35005672
Acta Anaesthesiol Scand. 2021 Jan;65(1):68-75
pubmed: 32929715
J Rheumatol. 2002 Nov;29(11):2371-8
pubmed: 12415594
Wien Klin Wochenschr. 2021 Apr;133(7-8):303-311
pubmed: 33534047
J Med Virol. 2021 Jan;93(1):51-55
pubmed: 32484975
BMJ. 2021 Feb 11;372:n311
pubmed: 33574135
Eur Respir J. 2022 Oct 20;60(4):
pubmed: 35361632